FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570274297> ?p ?o ?g. }

• W2570274297 endingPage "S202" @default.
• W2570274297 startingPage "S201" @default.
• W2570274297 abstract "Malignant pleural mesothelioma (MPM) is an aggressive cancer of the lining of the chest wall and lung, its aetiology lies in asbestos exposure. With over 2,500 people diagnosed each year, the UK has the highest incidence of mesothelioma in the world. Chemotherapy is an established treatment for MPM but response rates are variable, evidence is lacking in new drug therapies and mortality remains high (in the UK half of patients die within 8.5 months of diagnosis) (Maggioni 2016, HSCIC 2015). Surgery is therefore an important option. Very little robust, randomized controlled trial evidence (RCT) exists regarding surgical interventions for mesothelioma and many studies are observational (Cao et al 2014). This has prompted global variations in surgical approaches (Mclean 2013). Extended Pleurectomy Decortication (EPD) is a surgery for patients considered to have resectable MPM. EPD involves the removal of the lining of the chest wall, lining of the lung, with the sac of the heart and/or diaphragm (as required to achieve complete tumor removal) but leaving the lung in-situ. However, evidence on survival or symptom improvement benefits of this surgery is limited (Cao et al 2014, Teh et al 2011). Challenges in surgical research are the lack of clinical trials and few patients choosing to enter RCTs for surgery (Treasure & Morton, 2012, Horton 1996). Potential explanations for this include restrictive trial regulation, patients declining randomization, and difficulties in recruitment practice such as presenting trial arm options neutrally (Treasure & Morton 2012). The Mesothelioma and Radical Surgery 2 (MARS 2) Trial, a UK based study, will evaluate whether EPD can improve the length and/or quality of life in patients with surgically treatable disease and its cost-effectiveness. It will randomize participants to chemotherapy or chemotherapy plus surgery. The feasibility stage has demonstrated the ability to recruit and randomize to this study and the plan is to proceed to full trial. This paper presents findings from a nested qualitative patient experience sub-study within MARS 2 that investigated patient experience of the study interventions. It more specifically identifies the support and information needs for people regarding i) the interventions (surgery and chemotherapy) and ii) trial recruitment, consent and participation. This paper focuses on the findings related to support needs of the trial interventions. A summary of results will be provided along with reflections on the implications for future practice. An in-depth longitudinal qualitative study with interviews of 16 participants randomized to chemotherapy (n=8) and chemotherapy + surgery (n=8). Interviews were conducted after randomization (but before surgery in the surgical cohort). Surgical patients had an additional interview post-surgery. Framework analysis methods were used (Ritchie and Lewis, 2014). Follow-up interviews were at 6 and 12 months post-randomization. This paper presents findings up to and including the 6 months follow-up. Participants reported being well informed about their illness, but had struggled to absorb and understand the extent of information delivered at diagnosis. This was influenced by the range of significant subjects that were covered in a number of consultations with different healthcare staff providing distinct specialist services. The topics discussed included diagnostic information about mesothelioma, treatment options and consequences, trials processes and logistics, and legal and financial information regarding classification of MPM as an industrial disease. Despite feeling well informed about their treatment some participants reported not being prepared for the full extent of the problems they experienced. Both chemotherapy and surgery were challenging treatments although they were associated with different physical effects. Adverse consequences of treatment were described including neutropenic sepsis and dehydration post chemotherapy, and bleeding, prolonged pneumothorax and infection post-surgery. For most participants pain and breathlessness were experienced post-surgery while nausea, anorexia, taste changes and constipation were associated with chemotherapy. Fatigue that impacted on daily living was experienced by both groups. Interventions to manage the consequences of treatment were recounted; some had been recommended by healthcare staff while others had been developed by patients from their own initiative. Participants reported struggling to cope with the effect of treatment whilst trying to deal with the broader context of coming to terms with their illness. Uncertainty was expressed in relation to treatment plans (exacerbated by the logistics surrounding participation in a clinical trial), severity and duration of side effects, rehabilitation and recovery and treatment outcomes. Participants employed a number of strategies to help with coping. These included ‘playing things down’, ‘weighing the balance’, ‘managing expectations’, ‘taking control’ ‘manning up’ and ‘trust in the doctor and/or treatment’. Many of these strategies facilitated staying positive, maintaining hope and finding comfort which was important to participants. Family members played a key role in coping. A diverse range of healthcare staff provided information, advice and practical interventions across the care pathway from community, surgical, respiratory and oncology services. Patient’s perspectives on the experience of receiving radical surgery and/or chemotherapy for mesothelioma were identified by the study. This provided valuable insights into their impact on patient’s feelings about their illness and treatment and how they coped with the challenges they were presented with. Multiple sources of uncertainty were expressed by participants. The contribution of healthcare staff to supporting coping and providing information and advice was appraised positively by participants. However, we identified that fragmentation could occur due to the diverse services involved in providing care with no single point of contact or co-ordination. Understanding the patient’s perspective of the challenges associated with treatment, alongside their strategies for coping, provides insights for the services that can support patients undergoing arduous treatments for mesothelioma. The study reveals ways to facilitate strategies to help patients manage the condition, as well as treatment side-effects. Interventions to reduce uncertainty have been identified as a priority for service improvement." @default.
• W2570274297 created "2017-01-13" @default.
• W2570274297 creator A5085293349 @default.
• W2570274297 date "2017-01-01" @default.
• W2570274297 modified "2023-09-26" @default.
• W2570274297 title "NU03.01 Supporting Patients Undergoing Radical Treatments EPD – MARS Study" @default.
• W2570274297 doi "https://doi.org/10.1016/j.jtho.2016.11.178" @default.
• W2570274297 hasPublicationYear "2017" @default.
• W2570274297 type Work @default.
• W2570274297 sameAs 2570274297 @default.
• W2570274297 citedByCount "0" @default.
• W2570274297 crossrefType "journal-article" @default.
• W2570274297 hasAuthorship W2570274297A5085293349 @default.
• W2570274297 hasBestOaLocation W25702742971 @default.
• W2570274297 hasConcept C126322002 @default.
• W2570274297 hasConcept C141071460 @default.
• W2570274297 hasConcept C142724271 @default.
• W2570274297 hasConcept C168563851 @default.
• W2570274297 hasConcept C2776256026 @default.
• W2570274297 hasConcept C2777407522 @default.
• W2570274297 hasConcept C2778995398 @default.
• W2570274297 hasConcept C2779688492 @default.
• W2570274297 hasConcept C61434518 @default.
• W2570274297 hasConcept C71924100 @default.
• W2570274297 hasConceptScore W2570274297C126322002 @default.
• W2570274297 hasConceptScore W2570274297C141071460 @default.
• W2570274297 hasConceptScore W2570274297C142724271 @default.
• W2570274297 hasConceptScore W2570274297C168563851 @default.
• W2570274297 hasConceptScore W2570274297C2776256026 @default.
• W2570274297 hasConceptScore W2570274297C2777407522 @default.
• W2570274297 hasConceptScore W2570274297C2778995398 @default.
• W2570274297 hasConceptScore W2570274297C2779688492 @default.
• W2570274297 hasConceptScore W2570274297C61434518 @default.
• W2570274297 hasConceptScore W2570274297C71924100 @default.
• W2570274297 hasIssue "1" @default.
• W2570274297 hasLocation W25702742971 @default.
• W2570274297 hasLocation W25702742972 @default.
• W2570274297 hasOpenAccess W2570274297 @default.
• W2570274297 hasPrimaryLocation W25702742971 @default.
• W2570274297 hasRelatedWork W138749830 @default.
• W2570274297 hasRelatedWork W1973042618 @default.
• W2570274297 hasRelatedWork W2027444993 @default.
• W2570274297 hasRelatedWork W2071109990 @default.
• W2570274297 hasRelatedWork W2081773521 @default.
• W2570274297 hasRelatedWork W2093424646 @default.
• W2570274297 hasRelatedWork W2102995548 @default.
• W2570274297 hasRelatedWork W2571503142 @default.
• W2570274297 hasRelatedWork W3159435981 @default.
• W2570274297 hasRelatedWork W40593936 @default.
• W2570274297 hasVolume "12" @default.
• W2570274297 isParatext "false" @default.
• W2570274297 isRetracted "false" @default.
• W2570274297 magId "2570274297" @default.
• W2570274297 workType "article" @default.